Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial

Mads Israelsen(University of Southern Denmark), Katrine Holtz Thorhauge(University of Southern Denmark), Peter Andersen(Odense University Hospital), Katrine Prier Lindvig(University of Southern Denmark), Bjørn Stæhr Madsen(Odense University Hospital), Maria Kjærgaard(Central Denmark Region), Jonel Trebicka(Klinik für Schlafmedizin), Stine Johansen(University of Southern Denmark), Aleksander Krag(University of Southern Denmark), Johanne Kragh Hansen(Odense University Hospital), Jelle Matthijnssens(Rega Institute for Medical Research), Mathias Mann(Odense University Hospital), Roland Henrar, Cristina Legido‐Quigley(Steno Diabetes Centers), Ditlev Nytoft Rasmussen(Odense University Hospital), Hans Olav Melberg(Odense University Hospital), Manimozhiyan Arumugam(University of Copenhagen), Nikolaj Torp(University of Southern Denmark), M.A. Karsdal(Nordic Bioscience (Denmark)), Maja Thiele(Odense University Hospital), Peer Bork(Max Delbrück Center), Ema Anastasiadou(Higher Colleges of Technology), Sönke Detlefsen(Odense University Hospital), Torben Hansen(Steno Diabetes Centers), Camilla Dalby Hansen(University of Southern Denmark), Hans Israelsen(Odense University Hospital)
˜The œLancet. Gastroenterology & hepatology
March 6, 2023
Cited by 74


Related Papers